Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect, Nature, vol.77, issue.7294, pp.96-100, 2010. ,
DOI : 10.1038/nature08960
Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System, Antimicrobial Agents and Chemotherapy, vol.54, issue.9, pp.3641-50, 2010. ,
DOI : 10.1128/AAC.00556-10
-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus, Journal of Medicinal Chemistry, vol.53, issue.19, pp.7202-7220, 2010. ,
DOI : 10.1021/jm100863x
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir., Antiviral Therapy, vol.18, issue.7, pp.931-971, 2013. ,
DOI : 10.3851/IMP2674
Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate, Antiviral Therapy, vol.19, issue.5, pp.511-520, 2014. ,
DOI : 10.3851/IMP2718
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection, New England Journal of Medicine, vol.370, issue.3 ,
DOI : 10.1056/NEJMoa1306218
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options, New England Journal of Medicine, vol.368, issue.20 ,
DOI : 10.1056/NEJMoa1214854
Sofosbuvir and Ribavirin Therapy for the Treatment of HIV/HCV Coinfected Patients With HCV GT 1-4 Infection: The PHOTON 1 and 2 Trials, Hepatology, vol.60, issue.A195, p.87, 2014. ,
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study, The Lancet, vol.385, issue.9973, pp.1098-106, 2015. ,
DOI : 10.1016/S0140-6736(14)62483-1
Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation, Gastroenterology, vol.148, issue.1, pp.108-125, 2015. ,
DOI : 10.1053/j.gastro.2014.10.001
Recommendations for testing, managing, and treating hepatitis C ,
Sofosbuvir plus Ribavirin for the Treatment of Russian Patients with Chronic HCV Genotype 1 or 3 infection, Hepatology, vol.60, issue.A982, p.134, 2014. ,
Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry, Journal of Hepatology, vol.62, issue.5, pp.1040-1046, 2015. ,
DOI : 10.1016/j.jhep.2014.10.044
Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4, Journal of Hepatology, vol.63, issue.3, pp.581-586, 2015. ,
DOI : 10.1016/j.jhep.2015.04.023
Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population, Hepatology, vol.60, issue.A46, p.55, 2014. ,
O007 : All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: Interim report from the HCV-target real world experience, Journal of Hepatology, vol.62, issue.A007, p.183, 2015. ,
DOI : 10.1016/S0168-8278(15)30014-3
LP08 : Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: Real-world experience from HCV-target, Journal of Hepatology, vol.62, issue.LP08, p.263, 2015. ,
DOI : 10.1016/S0168-8278(15)30162-8
The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study, Liver International, vol.39, issue.Suppl 1, 2009. ,
DOI : 10.1097/01.mcg.0000142583.00102.45